Skip to main content
SpringerLink
Log in

Dopamine-receptor agonists: Mechanisms underlying autoreceptor selectivity

I. Review of the evidence

  • Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Agid, Y., Barroche, G., Bonnet, A. M., Javoy-Agid, F., Kato, G., Lhermitte, F., Pollak, P., Signoret, J. L.: Dopamine receptor stimulating agonists in the treatment of Parkinson's disease. Biomedicine30, 67–71 (1979).

    PubMed  Google Scholar 

  • Ahlenius, S.: An analysis of behavioral effects produced by drug-induced changes of dopaminergic neurotransmission in the brain. Scand. J. Psychol.20, 59–64 (1979).

    PubMed  Google Scholar 

  • Ahlenius, S., Archer, T., Tandberg, B., Hillegaart, V.: Effects of (-)-3-(3-hydoxy-phenyl)-N-n-propylpiperidine (3-PPP), alone and in combination with haloperidol (HPD), on conditioned avoidance behavior, catalepsy and treadmill performance in the rat. Progr. Neuro-Psychopharmacol. Biol. Psychiat. (suppl.),65 (abstr. no. 5) (1983).

  • Ahlenius, S., Archer, T., Tandberg, B., Hillegaart, V.: Effects of (-)-3-PPP on acquisition and retention of a conditioned avoidance response in the rat. Psychopharmacol.84, 441–445 (1984 a).

    Google Scholar 

  • Ahlenius, S., Hillegaart, V., Magnusson, O., Lundström, J.: Behavioral and biochemical effects of subchronic treatment with (-)-3-(3-hydroxyphenyl)N-n-propylpiperidine in the rat: dopamine receptor sensitivity and tolerance. J. Neural Transm.60, 103–113 (1984 b).

    PubMed  Google Scholar 

  • Ahlenius, S., Svensson, L., Hillegaart, V., Thorberg, O.: Antagonism by haloperidol of the suppression of exploratory locomotor activity induced by the local application of (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine into the nucleus accumbens of the rat. Experientia40, 858–859 (1984 c).

    PubMed  Google Scholar 

  • Andén, N.-E.: Regulation of monoamine synthesis and utilization by receptors. In: Handbook of Experimental Pharmacology (Szekeres, L., ed.), pp. 429–462. Berlin-Heidelberg-New York: Springer. 1980.

    Google Scholar 

  • Andén, N.-E., Grabowska-Andén, M., Liljenberg, B.: Demonstration of autoreceptors on dopamine neurons in different brain regions of rats treated with gamma-butyrolactone. J. Neural Transm.58, 143–152 (1983 a).

    PubMed  Google Scholar 

  • Andén, N.-E., Nilsson, H., Ros, E., Thornström, U.: Effect of B-HT 920 and B-HT 933 on dopamine and noradrenaline autoreceptors in the rat brain. Acta Pharmacol. et Toxicol.,52, 51–56 (1983 b).

    Google Scholar 

  • Andén, N.-E., Golembiowska-Nikitin, K., Nilsson, H., Ros, E., Thornström, U.: Effects of two azepine derivatives (B-HT 920 and B-HT 933) on pre-and postsynaptic dopamine receptors in the brain. Acta Pharmaceut. Suec. (suppl. 1983: 1), 154–164 (1983 c).

  • Angrist, B., Rotrosen, J., Gershon, S.: Responses to apomorphine, amphetamine and neuroleptics in schizophrenic subjects. Psychopharmacol.67, 31–38 (1980).

    Google Scholar 

  • Arbilla, S., Langer, S. Z.: Differential effects of the stereoisomers of 3-PPP on dopaminergic and cholinergic neurotransmission in superfused slices of the corpus striatum. Naunyn-Schmiedeberg's Arch. Pharmacol.327, 6–13 (1984).

    Google Scholar 

  • Arbilla, S., Dennis, T., Langer, S. Z., Niddam, R., Scatton, B.: Pretreatment with reserpine does not modify the amphetamine-induced release of endogenous dopamine in striatal slices. Br. J. Pharmacol, (suppl.)82, 249 P (1984).

  • Arnt, J.: Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol. Toxicol.51, 321–329 (1982).

    Google Scholar 

  • Arnt, J.: Differential behavioural effects of dopamine agonists in developing rats: a study of 3-PPP enantiomers. Eur. J. Pharmacol.91, 273–278 (1983).

    PubMed  Google Scholar 

  • Arnt, J., Hyttel, J.: Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats. J. Neural Transm.60, 205–223 (1984 a).

    PubMed  Google Scholar 

  • Arnt, J., Bogeso, K. P., Christensen, A. V., Hyttel, J., Larsen, J.-J., Svendsen, O.: Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers. Psychopharmacol.81, 199–207 (1983 a).

    Google Scholar 

  • Arnt, J., Christensen, A. V., Hyttel, J., Larsen, J.-J., Svendsen, O.: Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity. Eur. J. Pharmacol.86, 185–198 (1983 b).

    Google Scholar 

  • Bacopoulos, N.: Dopaminergic3H-agonist receptors in rat brain. New evidence on localization and pharmacology. Life Sci.34, 307–315 (1984).

    PubMed  Google Scholar 

  • Baldessarini, R. J., Tarsy, D.: Tardive dyskinesia. In: Psychopharmacology: A Generation of Progress (Lipton, M. A., DiMascio, A., Killam, K. F., eds.), pp. 993–1004. New York: Raven Press. 1978.

    Google Scholar 

  • Bardelay, C., Cousty, D., Hunt, P.: Different pre- and postsynaptic effects of 3-PPP enantiomers. Br. J. Pharmacol, (suppl.)80, 676 P (1983).

  • Besser, G. M., Wass, J. A. H., Thorner, M. O.: Bromocriptine in the medical management of acromegaly. Adv. Biochem. Psychopharmacol.23, 191–198 (1980).

    PubMed  Google Scholar 

  • Billingsley, M. L., Roth, R. H.: Dopamine agonists stimulate protein carboxymethylation in striatal synaptosomes. J. Pharmacol. Exp. Ther.223, 681–688 (1982).

    PubMed  Google Scholar 

  • Bitran, M., Bustos, G.: On the mechanism of presynaptic autoreceptormediated inhibition of transmitter synthesis in dopaminergic nerve terminals. Biochem. Pharmacol.31, 2851–2860 (1982).

    PubMed  Google Scholar 

  • Brown, F., Campbell, W.: Comparison of the effects of 3-PPP and its enantiomers on emesis, plasma prolactin levels and CNS dopamine turnover. Br. J. Pharmacol.81, 45 P (1984).

  • Brown, F., Campbell, W., Mitchell, P., Randall, K.: Dopamine autoreceptor agonism defined by inhibition of L-DOPA synthesis and spiperone-sensitive exploratory locomotion. Br. J. Pharmacol.82, 305 P (1984).

  • Bunney, B. S., Meltzer, L. T., Kauer, J. A., Chiodo, L. A.: (±)-3-PPP: a selective dopamine autoreceptor agonist? Electrophysiological studies in the basal ganglia. Acta Pharmaceut. Suec. (suppl. 1983: 1), 138–144 (1983).

  • Carlsson, A.: Dopaminergic autoreceptors. In: Chemical Tools in Catecholamine Research, Vol. II (Almgren, O., Carlsson, A., Engel, J., eds.), pp. 219–224. Amsterdam: North-Holland. 1975.

    Google Scholar 

  • Carlsson, A.: Dopamine receptor agonists: Intrinsic activity vs. state of the receptor. J. Neural Transm.57, 309–315 (1983).

    PubMed  Google Scholar 

  • Carlsson, A., Löfberg, L.: In vivo displacement by 3-PPP enantiomers of N,N-dipropyl-5,6-ADTN from rat striatal dopamine receptor binding sites. Manuscript submitted (1985).

  • Cedarbaum, J., Aghajanian, G. K.: Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur. J. Pharmacol.44, 375–385 (1977).

    PubMed  Google Scholar 

  • Chiodo, L. A., Bunney, B. S.: Electrophysiological studies on EMD 23448, an indolyl-3-butylamine, in the rat: a putative selective dopamine autoreceptor agonist. Neuropharmacol.22, 1087–1093 (1983).

    Google Scholar 

  • Clark, D., Carlsson, A., Hjorth, S., Svensson, K., Engel, J., Sanchez, D.: Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioural studies. Eur. J. Pharmacol.83, 131–134 (1982).

    PubMed  Google Scholar 

  • Clark, D., Carlsson, A., Hjorth, S., Engel, J., Lindberg, P.: The effect of the enantiomers of 3-PPP on conditioned avoidance in the rat. Psychopharmacol.81, 14–17 (1983 a).

    Google Scholar 

  • Cark, D., Carlsson, A., Hjorth, S., Svensson, K., Liljequist, S., Engel, J., Engberg, G., Svensson, T., Wikström, H.: Is 3-PPP a potential antipsychotic agent? Acta Pharmaceut. Suec. (suppl. 1983: 1), 145–153 (1983 b).

  • Clark, D., Hjorth, S., Carlsson, A.: (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis. Eur. J. Pharmacol.106, 185–189 (1984 a).

    PubMed  Google Scholar 

  • Clark, D., Engberg, G., Pileblad, E., Svensson, T. H., Carlsson, A., Freeman, A. S., Bunney, B. S.: The effects of novel dopaminergic agonists on the nigrostriatal dopamine system. Clin. Neuropharmacol.7 (suppl. 1), S 45 (1984 b).

    Google Scholar 

  • Clark, D., Engberg, G., Pileblad, E., Svensson, T. H., Carlsson, A., Freeman, A. S., Bunney, B. S.: An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system. Naunyn-Schmiedeberg's Arch. Pharmacol.1985a.

  • Clark, D., Hjorth, S., Carlsson, A.: Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J. Neural Transm.62 (1985 c).

  • Clark, D., Hjorth, S., Svensson, K., Carlsson, A.: (-)-3-PPP-induced changes in the behavioural and biochemical actions of d-amphetamine in the rat. Manuscript submitted (1985 d).

  • Clemens, J. A., Fuller, R. W., Phebus, L. A., Smalstig, B. B., Hynes, M. D., Cassady, J. M., Nichols, D. E., Kelly, E., Persons, P.: Stimulation of presynaptic dopamine autoreceptors by 4-(2-di-n-propylamino-ethyl)indole (DPAI). Life Sci.34, 1015–1022 (1984).

    PubMed  Google Scholar 

  • Corsini, G. U., Del Zompo, M., Manconi, S., Cianchetti, C., Mangoni, A., Gessa, G. L.: Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv. Biochem. Psychopharmacol.16, 645–648 (1977 a).

    PubMed  Google Scholar 

  • Corsini, G. U., Del Zompo, M., Manconi, S., Piccardi, M. P., Onali, P. L., Mangoni, A.: Evidence for dopamine receptors in the human brain mediating sedation and sleep. Life Sci.20, 1613–1618 (1977 b).

    PubMed  Google Scholar 

  • Corsini, G. U., Horowski, R., Rainer, R., Del Zompo, M.: Treatment of Parkinson's disease with a dopamine partial agonist. Soc. Neurosci. Abstr.10, 290 (1984).

    Google Scholar 

  • Cox, B.: Dopamine. In: Body temperature; regulation, drug effects and therapeutic implications (Lomax, P., Schonbaum, E., eds.), pp. 231–255. New York: Marcel Dekker. 1979.

    Google Scholar 

  • Creese, I., Stewart, K., Snyder, S. H.: Species variations in dopamine receptor binding. Eur. J. Pharmacol.60, 55–66 (1979).

    PubMed  Google Scholar 

  • Dettmar, P. W., Lynn, A. G., Tulloch, I. F.: Neuropharmacological studies in rodents of the action of RX 781094, a new selective alpha2-adrenoceptor antagonist. Neuropharmacol.22, 729–737 (1983).

    Google Scholar 

  • Dlabac, A., Krejci. I.: Central dopaminergic effects of ergoline derivatives. Act. Nerv. Super. (Praha)22, 208–209 (1980).

    Google Scholar 

  • Elam, M., Clark, D., Engberg G., Svensson, T. H.: Effects of the enantiomers of the dopamine (DA) autoreceptor agonist 3-PPP on locus coeruleus neurons. Progr. Neuro-Psychopharmacol. Biol. Psychiat. (suppl.) 123 (abstr. no. 124) (1983).

  • Elam, M., Clark, D., Engberg, G., Svensson, T. H.: Effects of the enantiomers of 3-PPP on locus coeruleus neurons. Manuscript submitted (1985).

  • Eriksson, E., Modigh, K., Carlsson, A., Wikström, H.: Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers. Eur. J. Pharmacol.96, 29–36 (1983).

    PubMed  Google Scholar 

  • Feenstra, M.: Dopamine receptor agonists; neuropharmacological and bioanalytical evaluation, pp. 1–252. Thesis, University of Groningen, 1984.

  • Feenstra, M. G. P., Rollema, H., Mulder, T. B. A., Westerink, B. H. C., Horn, A. S.:In vivo dopamine receptor binding studies with a non-radioactively labelled agonist, dipropyl-5,6-ADTN. Life Sci.32, 1313–1323 (1983).

    PubMed  Google Scholar 

  • Fenton, H. M., Hall, N. R., Gerhardt, S., Noreika, L., Neale, R., Liebman, J. M.: Avoidance and ICSS behavioral models dissociate TL-99 and 3-PPP from dopamine receptor antagonists. Eur. J. Pharmacol.91, 421–430 (1983).

    PubMed  Google Scholar 

  • Ferrier, I. N., Johnstone, E. C., Crow, T. J.: Clinical effects of apomorphine in schizophrenia. Brit. J. Psychiat.144, 341–348 (1984).

    PubMed  Google Scholar 

  • Fibiger, H. C., Zis, A. P., Phillips, A. G.: Haloperidol-induced disruption of conditioned avoidance responding: attenuation by prior training or by anticholinergic drugs. Eur. J. Pharmacol.30, 309–314 (1975).

    PubMed  Google Scholar 

  • Fowler, C.: Assessment of dopamine autoreceptor functionin vitro. Presented at the IUPHAR 9th Int. Congr. of Pharmacol., London, July 29th-August 3rd, 1984, Abstr. no. 1172 P (1984).

  • Fowler, C. J., Thorell, G., Andersson, M., Hall, H., Magnusson, O.: Inhibition of striatal synaptosomal tyrosine hydroxylation by dopamine agonists-a useful model for the study of presynaptic dopamine autoreceptorsin vitro? Manuscript submitted (1985).

  • George, S. R., Watanabe, M., Seeman, P.: The brain D2 dopamine receptor differs from the pituitary D2 receptor, as detected by (-)-3-PPP. Soc. Neurosci. Abstr.9, 31 (1983).

    Google Scholar 

  • George, S. R., Watanabe, M., Seeman, P.: D2 dopamine receptor interactions with agonists and antagonists are modulated by sodium ions. Soc. Neurosci. Abstr.10, 278 (1984).

    Google Scholar 

  • George, S. R., Watanabe, M., Seeman, P.: Dopamine D2 receptors in brain and anterior pituitary recognize agonist and antagonist actions of (-)-3-PPP. Manuscript submitted (1985).

  • Goldstein, M., Freedman, L. S., Backström, T.: The inhibition of catecholamine biosynthesis by apomorphine. J. Pharm. Pharmacol.22, 716–717 (1970).

    Google Scholar 

  • Gower, A. J., Berendsen, H. H. G., Princen, M. M., Broekkamp, C. L. E.: The yawning-penile erection syndrome as a model for putative dopamine autoreceptor activity. Eur. J. Pharmacol.103, 81–89 (1984).

    PubMed  Google Scholar 

  • Grabowska-Andén, M., Andén, N.-E.: Stimulation of postsynaptic DA2 receptors produces jerks in reserpine-treated rats. J. Pharm. Pharmacol.35, 543–545 (1983).

    PubMed  Google Scholar 

  • Grigoriadis, D., Seeman, P.: Sodium ions convert brain D2 dopamine receptors from high to low affinity for dopamine agonists. Soc. Neurosci. Abstr.9, 31 (1983).

    Google Scholar 

  • Grigoriadis, D., Seeman, P.: The dopamine/neuroleptic receptor. Can. J. Neurol. Sci.11 (suppl. 1), 108–113 (1984).

    PubMed  Google Scholar 

  • Gunne, L.-M., Bàràny, S.: Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacol.50, 237–240 (1976).

    Google Scholar 

  • Hacksell, U., Arvidsson, L.-E., Svensson, U., Nilsson, J. L. G., Sanchez, D., Wikström, H., Lindberg, P., Hjorth, S., Carlsson, A.: 3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity. J. Med. Chem.24, 1475–1482 (1981).

    PubMed  Google Scholar 

  • Herz, A.: Drugs and the conditioned avoidance response. Intern. Rev. Neurobiol.2, 229–277 (1960).

    Google Scholar 

  • Hjorth, S.: On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers (Thesis). Acta Physiol. Scand.118, suppl. 517, 1–52 (1983).

    PubMed  Google Scholar 

  • Hjorth, S., Carlsson, A., Lindberg P., Sanchez, D., Wikström, H., Arvidsson, L.-E., Hacksell, U., Nilsson, J. L. G., Svensson, U.: A new centrally acting DA-receptor agonist with selectivity for autoreceptors. Psychopharmacol. Bull.16, 85–90 (1980).

    Google Scholar 

  • Hjorth, S., Carlsson, A., Wikström, H., Lindberg, P., Sanchez, D., Hacksell, U., Arvidsson, L.-E., Svensson, U., Nilsson, J. L. G.: 3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci.28, 1225–1238 (1981).

    PubMed  Google Scholar 

  • Hjorth, S., Carlsson, A., Clark, D., Svensson, K., Wikström, H., Sanchez, D., Lindberg, P., Hacksell, U., Arvidsson, L.-E. Johansson, A., Nilsson, J. L. G.: Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacol.81, 89–99 (1983).

    Google Scholar 

  • Hjorth, S., Carlsson, A., Clark, D., Svensson, K.: Central dopaminergic actions of (+)- and (-)-3-PPP in relation to previous synaptic activity. Soc. Neurosci. Abstr.10, 239 (1984 a).

    Google Scholar 

  • Hjorth, S., Clark, D., Carlsson, A.: 3-PPP enantiomers and brain sigma opiate sites; discrepancies betweenin vitro andin vivo observations. Presented at the IUPHAR satellite symposium “Dopamine 84”, Southampton, U. K., August 5–8, 1984. Proceedings: in press (1984 b).

  • Hjorth, S., Svensson, K., Carlsson, A., Wikström, H., Andersson, B., Sanchez, D., Arvidsson, L.-E., Nilsson, J. L. G., Johansson, A. M.: Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners to 3-PPP. Presented at the VIIIth Int. Symp. on Med. Chem., August 27–31, 1984, Uppsala, Sweden. Proceedings: in press (1984 c).

  • Hjorth, S., Carlsson, A., Clark, D., Svensson, K., Sanchez, D.: Dopamine-receptor mediated hypothermia in rats induced by (+)- but not by (-)-3-PPP. Eur. J. Pharmacol.107, 299–304 (1985 a).

    PubMed  Google Scholar 

  • Hjorth, S., Clark, D., Carlsson, A.: Lack of functional evidence for the involvement of sigma opiate receptors in the actions of the 3-PPP enantiomers in central dopaminergic systems: discrepancies betweenin vitro andin vivo observations. Manuscript submitted (1985 b).

  • Hjorth, S., Clark, D., Svensson, K., Carlsson, A., Thorberg, S.-O.: Subchronic administration of (-)-3-PPP and central dopamine receptor sensitivity changes. Manuscript submitted (1985 c).

  • Horn, A. S., De Vries J., Dijkstra, F., Mulder, A. H.: Is TL-99 a selective presynaptic dopamine receptor agonist? Eur. J. Pharmacol.83, 35–45 (1982).

    PubMed  Google Scholar 

  • Hyttel, J.: Effects of neuroleptics on3H-haloperidol and3H-cis(Z)-flupenthixol binding and on adenylate cyclase activityin vitro. Life Sci23, 551–556 (1978).

    PubMed  Google Scholar 

  • Hyttel, J.: SCH 23390-the first selective dopamine Drantagonist. Eur. J. Pharmacol.91, 153–154 (1983).

    PubMed  Google Scholar 

  • Häggström, J.-E., Gunne, L. M., Carlsson, A., Wikström, H.: Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias. J. Neural Transm.58, 135–142 (1983).

    PubMed  Google Scholar 

  • Iorio, L. C., Barnett, A., Leitz, F. H., Houser, V. P., Kordoba, C. A.: SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther.226, 462–468 (1983).

    PubMed  Google Scholar 

  • Jackson, D., Carlsson, A., Hjorth, S., Lindberg, P.: A behavioural study of the changes in the central nervous system of mice after subchronic treatment with the selective dopamine autoreceptor agonist 3-PPP (dl-3-[3-hydroxyphenyl]-N-n-propylpiperidine). J. Neural Transm.53, 233–245 (1982).

    PubMed  Google Scholar 

  • Jeste, D. V., Cutler, N. R., Kaufman, C. A., Karoum, F.: Low-dose apomorphine and bromocryptine in neuroleptic-induced movement disorders. Biol. Psychiat.18, 1085–1091 (1983).

    PubMed  Google Scholar 

  • Kebabian, J. W., Calne, D. B.: Multiple receptors for dopamine. Nature277, 93–96 (1979).

    PubMed  Google Scholar 

  • Kehr, W.: Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism. Eur. J. Pharmacol.97, 111–119 (1984).

    PubMed  Google Scholar 

  • Kehr, W., Wachtel, H., Schneider, H. H.: Dopaminergic and antidopaminergic properties of ergolines structurally related to lisuride. Acta Pharmaceut. Suec. (suppl. 1983: 2), 98–110 (1983).

  • Keller, H. H., Imhof, R.: Effects of dopamine agonists and antagonists of various chemical classes on K–-induced3H-DA release from rat striatal slices. Progr. Neuro-Psychopharmacol. Biol. Psychiat. (suppl.) 188 (abstr. no. 260) (1983).

  • Kellogg, C., Lundborg, P.: Ontogenetic variations in responses to L-DOPA and monoamine receptor-stimulating agents. Psychopharmacol.23, 187–200 (1972).

    Google Scholar 

  • Kelly, P. A. T., Graham, D. L., McCulloch, J.: Specific alterations in local cerebral glucose utilisation following striatal lesions. Brain Res.233, 157–172 (1982).

    PubMed  Google Scholar 

  • Kobinger, W., Pichler, L.: Relation between central sympathoinhibitory and peripheral pre- and postsynaptic alpha-adrenoceptors as evaluated by different clonidine-like substances in rats. Naunyn-Schmiedeberg's Arch. Pharmacol.315, 21–27 (1980).

    Google Scholar 

  • Koch, S. W., Koe, B. K., Bacopoulos, N. G.: Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites. Eur. J. Pharmacol.92, 279–283 (1983).

    PubMed  Google Scholar 

  • Kolakowska, T.: Plasma prolactin during-treatment- with neuroleptic drugs: Clinical significance and some implications. In: Handbook of psychiatry and endocrinology (Beumont, P. J. V., Burrows, G. D., eds.), pp. 123–156. Amsterdam: Elsevier-Biomedical Press. 1982.

    Google Scholar 

  • Kozlowski, M. R., Marshall, J. E.: Plasticity of14C-2-deoxy-D-glucose incorporation into the neostriatum and related structures in response to dopamine neuron damage and apomorphine replacement. Brain Res.197, 167–183 (1980).

    PubMed  Google Scholar 

  • Langer, S. Z., Arbilla, S., Kamal, L., Cantrill, R.: Peripheral and central dopamine receptors modulating the release of neurotransmitters. Acta Pharmaceut. Suec. (suppl. 1983: 1), 108–117 (1983).

  • Largent, B. L., Gundlach, A. L., Snyder, S. H.: Psychotomimetic opiate receptors labelled and visualized with (+)-3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. Proc. Natl. Acad. Sci. (U.S.A.)81, 4983–4987 (1984).

    Google Scholar 

  • Lee, E. H. Y., Geyer, M. A.: Similarities of the effects of apomorphine and 3-PPP on serotonin neurons. Eur. J. Pharmacol.94, 297–303 (1983).

    PubMed  Google Scholar 

  • Lehmann, J., Langer, S. Z.: The striatal cholinergic interneuron: synaptic target of dopaminergic terminals? Neurosci.10, 1105–1120 (1983).

    Google Scholar 

  • Lehmann, J., Briley, M., Langer, S. Z.: Characterization of dopamine autoreceptor and3H-spiperone binding sitesin vitro with classical and novel dopamine receptor agonists. Eur. J. Pharmacol.88, 11–26 (1983).

    PubMed  Google Scholar 

  • Lieberman, A., Neophytides, A., Kuper-Smith, M., Casson, I., Durso, R., Foo, S. H., Khayali, M., Tartaro, T., Goldstein, M.: Treatment of Parkinson's disease with dopamine agonists: a review. Am. J. Med. Sci.278, 65–76 (1979).

    PubMed  Google Scholar 

  • Lloyd, K. G.: Neurotransmitter interactions related to central dopamine neurons. In: Essays in Neurochemistry and Neuropharmacology (Youdim et al., M. B. H., ed.), pp. 129–207. New York: Wiley. 1978.

    Google Scholar 

  • Magnusson, T., Carlsson, A., Lindberg, P., Sanchez, D.: Evidence for activation of dopaminergic autoreceptors by (-)-3-PPP. Acta Pharmaceut. Suec. (suppl. 1983: 1), 16–18 (1983).

  • Markstein, R., Lahaye, D.:In vitro effect of the racemic mixture and the (-)-enantiomer of N-n-propyl-3-(3-hydroxyphenyl)piperidine (3-PPP) on postsynaptic dopamine receptors and on a presynaptic dopamine autoreceptor. J. Neural Transm.58, 43–53 (1983).

    PubMed  Google Scholar 

  • Marsden, C. D., Parkes, J. D.: “On-off” effects in patients with Parkinson's disease on chronic levodopa therapy. LancetI, 292–296 (1976).

    Google Scholar 

  • Martin, G. E., Haubrich, D. R., Williams, M.: Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99. Eur. J. Pharmacol.76, 15–23 (1981).

    PubMed  Google Scholar 

  • McDevitt, J. T., Setler, P. E.: Differential effects of dopamine agonists in mature and immature rats. Eur. J. Pharmacol.72, 69–75 (1981).

    PubMed  Google Scholar 

  • Meltzer, H. Y., Simonovic, M.: Effect of 3-PPP, a putative dopamine autoreceptor agonist, on rat serum prolactin levels. Life Sci.29, 99–105 (1981).

    PubMed  Google Scholar 

  • Mereu, G., Fanni, B., Gessa, G. L.: General anesthetics prevent dopaminergic nerve stimulation by neuroleptics. In: Neurology and Neurobiology, Vol. 8 B; Catecholamines: Neuropharmacology and Central Nervous System-Theoretical Aspects (Usdin, E., Carlsson, A., Dahiström, A., Engel, J., eds.), pp. 353–358. New York: Alan R. Liss. 1984.

    Google Scholar 

  • Mikuni, M., Gudelsky, G. A., Simonovic, M., Meltzer, H. Y.: Interaction of (+)- and (-)-3-PPP with the dopamine receptor in the anterior pituitarygland. Life Sci.34, 239–246 (1984).

    PubMed  Google Scholar 

  • Mogilnicka, E., Klimek, V.: Drugs affecting dopamine neurons and yawning behaviour. Pharmacol. Biochem. Behav.7, 303–305 (1977).

    PubMed  Google Scholar 

  • Mogilnicka, E., Boissard, C. G., Delini-Stula, A.: Effects of apomorphine, TL-99 and 3-PPP on yawning in rats. Neuropharmacol.23, 19–22 (1984).

    Google Scholar 

  • Mulder, A. H., Draper, R., Sminia, P., Schoffelmeer, A. N. M., Stoof, J. C.: Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptorsin vitro. Eur. J. Pharmacol.107, 291–297 (1985).

    PubMed  Google Scholar 

  • Neale, R., Gerhardt, S., Liebman, J. M.: Effects of dopamine agonists, catecholamine depletors, cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys. Psychopharmacol.82, 20–26 (1984).

    Google Scholar 

  • Oberlander, C., Bardelay, C., Hunt, P. F.: Two distinct striatal dopamine mechanisms in the postsynaptic action of (-)-3-PPP. Presented at the IUPHAR satellite symposium “Dopamine 84”, Southampton, U.K., August 5–8, 1984. Proceedings: in press (1984).

  • Oberlander, C., Boissier, J. R.: Postsynaptic striatal dopamine agonist or antagonist actions of (+)- or (-)-3-PPP and modification after receptor deafferentation. J. Pharmacol. (Paris)14, 401–404 (1983).

    Google Scholar 

  • Palacios, J. M., Wiederbold, K.-H.: Presynaptic dopaminergic agonists modify brain glucose metabolism in a way similar to the neuroleptics. Neurosci. Letters50, 223–229 (1984).

    Google Scholar 

  • Parker, E. M., Cubeddu, L. X.: Evidence for autoreceptor modulation of endogenous dopamine release from rabbit caudate nucleusin vitro. J. Pharmacol. Exp. Ther.232, 492–500 (1985).

    PubMed  Google Scholar 

  • Parkes, D.: Bromocriptine. Adv. Drug Res.12, 247–344 (1977).

    PubMed  Google Scholar 

  • Pfeiffer, F. R., Wilson, J. W., Weinstock, J., Kuo, G. Y., Chambers, P. A., Holden, K. G., Hahn, R. A., Wardell, J. R., Tobia, A. J., Setler, P. E., Sarah, H. M.: Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetra-hydro-1H-3-benzazepines. J. Med. Chem.25, 352–358 (1982).

    PubMed  Google Scholar 

  • Pinnock, R. D.: Action of putative dopamine receptor agonists, TL-99, 3-PPP and RDS-127 on substantia nigra neurons. Brain Res.292, 190–193 (1984).

    PubMed  Google Scholar 

  • Plantjé, J. F., Hansen, H. A., Daus, F. J., Stoof, J. C.: The effects of SCH 23390, YM 09151-2, (+)- and (-)-3-PPP and some classical neuroleptics on D-1 and D-2 receptors in rat neostriatumin vitro. Eur. J. Pharmacol.105, 73–83 (1984).

    PubMed  Google Scholar 

  • Roth, R. H.: Dopamine autoreceptors: Pharmacology, function and comparison with postsynaptic dopamine receptors. Commun. Psychopharmacol.3, 429–445 (1979).

    PubMed  Google Scholar 

  • Roth, R. H., Bannon, M. J., Wolf, M. E., Billingsley, M. L.: Dopamine autoreceptors: Biochemical studies on their pharmacology, distribution and function. Acta Pharmaceut. Suec (suppl. 1983: 1), 99–107 (1983).

  • Saller, C. F., Salama, A. I.: Synaptosomal dopamine synthesis: effects of autoreceptor stimulation and treatments which alter intrasynaptosomal dopamine content. Progr. Neuro-Psychopharmacol. Biol. Psychiat. (suppl.)269 (abstr. no. 430) (1983).

  • Saller, C. F., Salama, A. I.: Dopamine synthesis in synaptosomes: relation of autoreceptor functioning to pH, membrane depolarisation, and intrasynaptosomal dopamine content. J. Neurochem.43, 675–688 (1984).

    PubMed  Google Scholar 

  • Scatton, B.: Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity. J. Pharmacol. Exp. Ther.220, 197–202 (1982).

    PubMed  Google Scholar 

  • Scatton, B., Zivkovic, B., Dedek, J.: Antidopaminergic properties of yohimbine. J. Pharmacol. Exp. Ther.215, 494–499 (1980).

    PubMed  Google Scholar 

  • Schorderet, M., Hjorth, S., Hacksell, U.: Differential effects of the enantiomers of 3-PPP on dopamine D1-receptors of isolated rabbit retina. J. Neural Transm.59, 1–7 (1984).

    PubMed  Google Scholar 

  • Seeman, P.: Brain dopamine receptors. Pharmacol. Revs.32, 229–313 (1980).

    Google Scholar 

  • Serra, G., Collu, M., Vargiu, L., Gessa, G. L.: Evidence that dopamine receptors controlling yawning and penile erection are not autoreceptors. Presented at the 14th CINP Congress, Florence, Italy, June 19–23, 1984 (abstr. no. P-389) (1984).

  • Sethy, V. M., Wenger, D.: Effect of dopaminergic drugs on striatal acetylcholine concentration. J. Pharm. Pharmacol.37, 73–74 (1985).

    PubMed  Google Scholar 

  • Setler, P. E., Sarau, C. L., Zirkle, C. L., Saunders, H. L.: The central effects of a novel dopamine agonist. Eur. J. Pharmacol.50, 419–430 (1978).

    PubMed  Google Scholar 

  • Shalaby, I. A., Dendel, P. S., Spear, L. P.: Differential functional ontogeny of dopamine presynaptic receptor regulation. Develop. Brain Res.1, 434–439 (1981).

    Google Scholar 

  • Shalaby, I. A., Spear, L. P.: Psychopharmacological effects of low and high doses of apomorphine during ontogeny. Eur. J. Pharmacol.67, 451–459 (1980).

    PubMed  Google Scholar 

  • Shepard, P. D., German, D. C.: Substantia nigra dopamine neurons: relationship between cell firing properties, anatomical localization and autoreceptor sensitivity. Soc. Neurosci. Abstr.8, 921 (1982).

    Google Scholar 

  • Sibley, D. R., DeLean, A., Creese, I.: Anterior pituitary dopamine receptors. J. Biol. Chem.257, 6351–6361 (1982 a).

    PubMed  Google Scholar 

  • Skirboll, L., Bunney, B. S.: The effects of acute and chronic haloperidol treatment on spontaneously firing neurons in the caudate nucleus of the rat. Life Sci.25, 1419–1434 (1979).

    PubMed  Google Scholar 

  • Skirboll, L. A., Grace, A. A., Bunney, B. S.: Dopamine auto- and postsynaptic receptors: Electrophysiological evidence for differential sensitivity to dopamine agonists. Science206, 80–82 (1979).

    PubMed  Google Scholar 

  • Sminia, P., Mulder, A. H.: Failure of 3-PPP to activate dopamine autoreceptorsin vitro. Eur. J. Pharmacol.89, 183–184 (1983).

    PubMed  Google Scholar 

  • Smith, R. C., Tamminga, C. A., Davis, J. M.: Effect of apomorphine on schizophrenic symptoms. J. Neural Transm.40, 171–176 (1977).

    PubMed  Google Scholar 

  • Sokoloff, L., Reivich, M., Kennedy, C., Des Rosiers, M. H., Patlak, C. S., Pettigrew, K. D., Sakurada, C., Shinohara, M.: The (14C)-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J. Neurochem.28, 13–36 (1977).

    PubMed  Google Scholar 

  • Sovner, R., DiMascio, A.: Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In: Psychopharmacology: A Generation of Progress (Lipton, M. A., DiMascio, A., Killam, K. F., eds.), pp. 1021–1032. New York: Raven Press. 1978.

    Google Scholar 

  • Ståhle, L., Ungerstedt, U.: Assessment of dopamine autoreceptor agonist properties of apomorphine, (+)-3-PPP and (-)-3-PPP by recording of yawning behaviour in rats. Eur. J. Pharmacol.98, 307–310 (1984).

    PubMed  Google Scholar 

  • Starke, K., Reimann, W., Zumstein, A., Hering, G.: Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus. Naunyn-Schmiedeberg's Arch. Pharmacol.305, 27–36 (1978).

    Google Scholar 

  • Starke, K., Spath, L., Lang, J. D., Adelung, C.: Further functionalin vitro comparison of pre- and postsynaptic dopamine receptors in the rabbit caudate nucleus. Naunyn-Schmiedeberg's Arch. Pharmacol.323, 298–306 (1983).

    Google Scholar 

  • Stoof, J. C., Kebabian, J. W.: Opposing roles for D-1- and D-2-dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature294, 366–368 (1981).

    PubMed  Google Scholar 

  • Stoof, J. C., Kebabian, J. W.: Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci.35, 2281–2296 (1984).

    PubMed  Google Scholar 

  • Strömbom, U.: On the functional role of pre- and postsynaptic catecholamine receptors in brain. (Thesis). Acta Physiol. Scand., suppl.431, 1–43 (1975).

    Google Scholar 

  • Sumners, C., De Vries, J. B., Horn, A. S.: Behavioural and neurochemical studies on apomorphine-induced hypomotility in mice. Neuropharmacol.20, 1203–1208 (1981 a).

    Google Scholar 

  • Sumners, C., De Vries, J. B., Dijkstra, D., Horn, A. S.: Involvement of both dopaminergic andα-adrenergic receptors in the hypomotility induced by dibenzoyl-6,7-ADTN. Eur. J. Pharmacol.70, 541–550 (1981 b).

    PubMed  Google Scholar 

  • Svensson, L., Ahknius, S.: Suppression of exploratory locomotor activity in the rat by the local application of (-)-3-PPP into the nucleus accumbens. Eur. J. Pharmacol.88, 393–397 (1983).

    PubMed  Google Scholar 

  • Tamminga, C. A., Gotts, M. D., Miller, M. R.: N-propyl-norapomorphine in the treatment of schizophrenia. Acta Pharmaceut. Suec. (suppl. 1983: 2), 153–158 (1983).

  • Tissari, A. H., Atzori, L., Galdieri, M. T.: Inhibition of dopamine synthesis in striatal synaptosomes by lisuride: stereospecific reversal by (-)-sulpiride. Naunyn-Schmiedeberg's Arch. Pharmacol.322, 89–91 (1983).

    Google Scholar 

  • Trulson, M. E., Trulson, V. M.: Chloral hydrate anesthesia alters the responsiveness of dorsal raphe neurons to psychoactive drugs. Life Sci.32, 949–956 (1982).

    Google Scholar 

  • Tsuruta, K., Frey, E. A., Grewe, C. W., Cote, T. E., Eskay, R. L., Kebabian, J. W.: Evidence that LY-141865 specifically stimulates the D-2-dopamine receptor. Nature292, 463–465 (1981).

    PubMed  Google Scholar 

  • Ungerstedt, U.: Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. (suppl.)367, 69–93 (1971).

    Google Scholar 

  • Van Oene, J. C., De Vries, J. B., Horn, A. S.: The effectiveness of yohimbine in blocking rat central dopamine autoreceptorsin vivo. Naunyn-Schmiedeberg's Arch Pharmacol.327, 304–311 (1984).

    Google Scholar 

  • Van Ree, J. M., Wolterink, G.: Injection of low doses of apomorphine into the nucleus accumbens of rats reduces locomotor activity. Eur. J. Pharmacol.72, 107–111 (1981).

    PubMed  Google Scholar 

  • Wachtel, H.: Central dopaminergic and antidopaminergic effects of ergot derivatives structurally related to lisuride. In: Lisuride and Other Dopamine Agonists (Calne et al., D. B., ed.), pp. 109–125. New York: Raven Press. 1983.

    Google Scholar 

  • Wachtel, H., Dorow, R.: Dual action on central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci.32, 421–432 (1983).

    PubMed  Google Scholar 

  • Wachtel, H., Ahlenius, S., Andén, N.-E.: Effects of locally applied dopamine to the nucleus accumbens on the motor activity of normal rats and following alph-methyltyrosine or reserpine. Psychopharmacol.63, 203–206 (1979).

    Google Scholar 

  • Wachtel, H., Rettig, K.- J., Seltz, A.: The central dopamine agonistic action of transdihydrolisuride is unmasked at supersensitive receptors. Naunyn-Schmiedeberg's Arch. Pharmacol.325 (suppl.), R 80 (abstr. no. 317) (1984).

  • Waggoner, W. G., McDermed, J., Leighton, H. J.: Presynaptic regulation of tyrosine hydroxylase in rat striatal synaptosomes by dopamine analogs. Molec. Pharmacol.18, 91–99 (1980).

    Google Scholar 

  • Waldmeier, P. C.: Biphasic effects of some dopamine agonists on striatal acetylcholine concentrations. Eur. J. Pharmacol.90, 115–120 (1983).

    PubMed  Google Scholar 

  • Walters, J. R., Roth, R. H.: Dopaminergic neurons: Anin vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg's Arch. Pharmacol.296, 5–14 (1976).

    Google Scholar 

  • Watling, K.: Interaction of the enantiomers of 3-PPP with postsynaptic dopaminesensitive adenylate cyclase in carp retina. Br. J. Pharmacol. (suppl.)80, 646 P (1983).

  • White, F., Wang, R. Y.: A10 dopamine neurons: Role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci.34, 1161–1170 (1984 a).

    PubMed  Google Scholar 

  • Wikström, H.: Centrally acting dopamine receptor stimulants with special reference to dopamine autoreceptors and stereoselectivity. (Thesis). Univ. of Uppsala, Uppsala, Sweden (1983).

    Google Scholar 

  • Williams, M., Pettibone, D. J., Martin, G. E.: Interaction of the enantiomers of 3-PPP (3-[3-hydroxyphenyl]-N-n-propylpiperidine) with dopaminergic systems in rat brain. Manuscript submitted (1984).

  • Wong, D. T., Bymaster, F. P., Reid, L. R., Fuller, R. W., Perry, K. W., Kornfeld, E. C.: Effect of a stereospecific D2-dopamine agonist on acetylcholine concentration in corpus striatum of rat brain. J. Neural Transm.58, 55–67 (1983).

    PubMed  Google Scholar 

  • Wreggett, K. A., Seeman, P.: Agonist high- and low-affinity states of the D2-dopamine receptor in calf brain. Partial conversion by guanine nucleotide. Molec. Pharmacol.25, 10–17 (1984).

    Google Scholar 

  • Yamada, K., Furukawa, T.: Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacol.67, 39–43 (1980).

    Google Scholar 

  • Zahniser, N. R., Molinoff, P. B.: Effect of guanine nucleotides on striatal dopamine receptors. Nature (London)275, 453–455 (1978).

    Google Scholar 

Download references

Author information

Author notes

  1. A. Carlsson

    Present address: Department of Pharmacology, University of Göteborg, Göteborg, Sweden

  2. D. Clark

    Present address: Laboratory of Neurophysiology, Center for Cell Biology, Sinai Hospital of Detroit, 6767 West Outer Drive, 48235, Detroit, MI, USA

Authors and Affiliations

  1. Department of Pharmacology, University of Göteborg, Göteborg, Sweden

    D. Clark & S. Hjorth

Authors
  1. D. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Hjorth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Carlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clark, D., Hjorth, S. & Carlsson, A. Dopamine-receptor agonists: Mechanisms underlying autoreceptor selectivity. J. Neural Transmission 62, 1–52 (1985). https://doi.org/10.1007/BF01260414

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01260414

Keywords

Search

Navigation